C
Christopher P. Cannon
Researcher at Brigham and Women's Hospital
Publications - 1165
Citations - 122136
Christopher P. Cannon is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 151, co-authored 1118 publications receiving 108906 citations. Previous affiliations of Christopher P. Cannon include University of Vermont & MedStar Washington Hospital Center.
Papers
More filters
Journal ArticleDOI
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin,Richard C. Becker,Andrzej Budaj,Christopher P. Cannon,Håkan Emanuelsson,Claes Held,Jay Horrow,Steen Husted,Stefan James,Hugo A. Katus,Kenneth W. Mahaffey,Benjamin M. Scirica,Allan M. Skene,Philippe Gabriel Steg,Robert F. Storey,Robert A. Harrington +15 more
TL;DR: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Journal ArticleDOI
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P. Cannon,Eugene Braunwald,Carolyn H. McCabe,Daniel J. Rader,Jean L. Rouleau,Rene Belder,Steven V. Joyal,Karen A. Hill,Marc A. Pfeffer,Allan M. Skene +9 more
TL;DR: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White,Christopher P. Cannon,Simon Heller,Steven E. Nissen,Richard M. Bergenstal,George L. Bakris,Alfonso Perez,Penny R. Fleck,Cyrus R. Mehta,Stuart Kupfer,Craig A. Wilson,William C. Cushman,Faiez Zannad +12 more
TL;DR: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo.
Journal ArticleDOI
C-Reactive Protein Levels and Outcomes after Statin Therapy
Paul M. Ridker,Christopher P. Cannon,David A. Morrow,Nader Rifai,Lynda M. Rose,Carolyn H. McCabe,Marc A. Pfeffer,Eugene Braunwald +7 more
TL;DR: Relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes are evaluated.